The Optejet® ophthalmic drug device is designed to precisely administer medication to the eye, potentially treating patients' conditions through gentler, more efficient dosing.
Read Press ReleaseFDA 510 (K) clearance was based on a pivotal clinical trial evaluating the safety and effectiveness of this novel eye-tracking-based amblyopia therapy vs eye patching, the gold standard.
Read Press ReleaseWhile traditional eye drop bottles require hand-eye coordination and deliver four to five times more medication than the human eye can hold, the Optejet® dispenser's human-centric design administers an easier, more accurate and appropriate dose directly where it is needed in the eye.
Read Press ReleaseLeading Ophthalmology Practice, Coastal Vision Medical Group Among First to Offer EVO Visian ICL in Southern California to Provide Visual Freedom from Glasses and Contact Lenses
Read Press ReleaseThe newly approved connected device will facilitate patient access and communication between patients and eye care providers, collect data, and provide a platform between home and office to optimize treatment for dry eye
Read Press ReleaseThe in-vitro studies performed in Glauconix's co-culture 3D conventional human outflow model confirm efficacy
Read Press Release3D Human Tissue Retina Vasculature model provides a new and novel approach to rapidly and efficiently screening numerous therapies for diabetic retinopathy and diabetic macular edema.
Read Press ReleaseNovaSight has announced that it is running a large, pivotal multi-center randomized controlled trial to assess the safety and effectiveness of an eye-tracking-based treatment for Amblyopia (Lazy Eye).
Read Press ReleaseAppointment reflects Glauconix Biosciences' expansion of their 3D Human Tissue model platform within the Ophthalmology space and brings their second commercial model closer to market
Read Press Release